Judge Shuts Down Actimmune Marketing MDL

By Evan Weinberger

Law360, New York (September 03, 2010, 11:23 AM ET) -- A federal judge has brought an end to multidistrict litigation claiming biotechnology company InterMune Inc. fraudulently promoted its drug Actimmune as a remedy for a deadly lung disease it was not approved to treat.

Judge Marilyn Hall Patel of the U.S. District Court for the Northern District of California on Wednesday dismissed the case with prejudice, ruling that the plaintiffs — a proposed class of patients as well as insurer Government Employees Health Association Inc. — had failed in their third attempt to bring actionable claims...
To view the full article, take a free trial now.

Already a subscriber? Click here to login

You must correct or enter the following before you can submit this form:

All fields required

  5. Required

Only Law360 gives you:

Non-stop coverage of high-stakes litigation across 30 practices

Real-time tracking and reports on 10,000+ companies, firms and industries

Over 80,000 attorney profiles with neutral data collected from active lawsuits

Research tools to find cases, court documents, attorneys and companies

Customized feeds and alerts that can easily be shared with colleagues

In-depth expert analysis from high-profile attorneys at top firms

Access to our vault with over 75,000 original articles